PF-Atlas › Clinical Trials › NCT05535959
A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor
VX-121/TEZ/D-IVA · Phase 1
Registry ID
NCT05535959
Phase
Phase 1
Status
Completed
Drug / intervention
VX-121/TEZ/D-IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2022-09-15
Enrollment
16
Locations
1
About this trial
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet (FDC) of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05535959 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.